DNTH - Dianthus Therapeutics, Inc. /DE/ | Scanr.ai
DNTH
Dianthus Therapeutics, Inc. /DE/
Manufacturing
|
Pharmaceutical Products
|
XNAS
104.09
2.48
2.44%
Jul 29, 3:59 PM EDT
Enlarge chart
Fullscreen chart
O 104.55H 105.855L 100C 101.61Vol 841.02K
Jul 28, 2026
Dianthus Therapeutics, Inc. /DE/
Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers,genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.
